
Will Casgevy, the first cell therapy using CRISPR gene editing, have net sales >$100M in 2024?
8
Ṁ110Ṁ330resolved Feb 16
Resolved
NO1H
6H
1D
1W
1M
ALL
This question is managed and resolved by Manifold.
Market context
Get
1,000 to start trading!
🏅 Top traders
| # | Trader | Total profit |
|---|---|---|
| 1 | Ṁ43 | |
| 2 | Ṁ26 | |
| 3 | Ṁ4 | |
| 4 | Ṁ0 | |
| 5 | Ṁ0 |
Sort by:
Price is $2.2 million per NYTimes: https://web.archive.org/web/20231214145621/https://www.nytimes.com/2023/12/08/health/fda-sickle-cell-crispr.html
So the number of treatments to reach that would actually be quite small. But the article also notes that the capacity will be extremely limited. Vertex has 9 centers approved to offer the treatment, and one of those says they can treat 5-10 a year.
$100 million seems like the right ballpark, and I think the chance they hit that in 2025 seems reasonably high, but for 2024 I'm not optimistic unless the figures from the NYTimes don't tell the full story or I am misreading them.
People are also trading
Related questions
Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
79% chance
When will commercial gene-editing therapy be available?
2041
Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
Will a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
59% chance
Will I receive any kind of gene therapy created using CRISPR before I die?
62% chance
Will we have gene therapy for a major strain of Crohn's disease by 2030?
26% chance
Will biopharma VC funding in one year have exceeded $100 billion USD by 2030?
70% chance
[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
27% chance
Will there be a CRISPR treatment for Ehlers-Danlos Syndromes before 2040?
52% chance
Which biotech scaleup will have the largest market cap in 2030?